Royalty Report: Drugs, cardiac, Biotechnology – Collection: 28242

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 19

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 19

Primary Industries

  • Drugs
  • cardiac
  • Biotechnology
  • Genome
  • Disease
  • Therapeutic
  • Delivery
  • Drug Discovery
  • Proteins
  • Congestive Heart Failure
  • Stem cells

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28242

License Grant
The University Board hereby grants to Licensee a royalty-bearing, exclusive worldwide license under licensed subject matter to manufacture, have manufactured, import, use, offer for sale and/or sell licensed products for use within field.
License Property
GENE THERAPY means therapeutic use of a designated gene (including therapeutic use of a homolog or derivative, or gene product thereof) which may be incorporated into vectors or other carriers, in a pharmaceutical composition that is administered by in vivo delivery (i.e. introduced inside the body) or by ex vivo delivery (i.e. introduced into cells or other complexes outside of the body which are subsequently introduced into the body). GENE THERAPY specifically excludes ANTISENSE THERAPY.

ANTISENSE THERAPY means therapeutic use of oligonucleotides or modified oligonucleotides that bind in a sequence specific manner to DNA or mRNA.

Field of Use
Field means Gene Therapy for treatment of heart disease and heart failure.

IPSCIO Record ID: 28224

License Grant
The UK University hereby grants to the Licensee
  (a)  an exclusive license in the Territory under the Licensed Technology to conduct research on, develop and commercialize the Licensed Technology, to manufacture, have manufactured, use and have used, market, sell, have sold, offer for sale, have offered for sale, import and export and have imported and exported the compositions, technology or inventions, and to practice (or practise) the processes or methods that are within or that constitute the Licensed Technology for use in the Field.
  (b)  the right to grant Sublicenses (with the right of such sublicensees to grant further sublicenses).
License Property
Licensor owns or has rights in certain technology regarding vectors and the capturing of genes.

Licensed Technology means Improvements, Inventions, Information and Know-How and Patents.
Patents means
  (a)  (i)  Patent number 5,767,336 granted in the United States of America entitled 'Gene Trap Vectors Comprising a Type II Transmembrane Domain', issued August 4,
  1998;
   (ii) Patent number 5,789,653 granted in the United States of America entitled 'Secretary Gene Trap', issued June 16, 1998;
   (iii)    Patent number 673,650 granted in Australia entitled 'Novel Vectors and Use Thereof for Capturing Target Genes', issued March 4, 1997

'Antisense Product' means a product which incorporates oligonucleotides that bind to either (a) mRNA to prevent the translation of mRNA, or protein production m vivo, or '(b) DNA to prevent the transcription of DNA into the mRNA copy of the gene in vivo; in each case, solely to the extent that such oligonucleotides (x) were directly developed from the practiceof any process or method claimed in the Patents or (y) contains a composition of matter claimed in the Patents, and (z) are covered by one or more Valid Claims.

Field of Use
'Field' means the use of vectors in biochemical, cellular and molecular biology research, development and commercialization relating to genes.

IPSCIO Record ID: 260408

License Grant
Licensor, an individual, hereby grants an exclusive, even as to Licensor, worldwide license, with the right to sublicense through multiple tiers of sublicense, under Licensors interest in the Licensed Patents for any purpose in the Field, including, without limitation, to develop, make, have made, use, sell, offer for sale, have sold and import Products in the Field.
License Property
The patent relates to methods for transferring genes into the heart and blood vessels.
Field of Use
The Field shall mean the treatment or prevention of heart failure using products that act by the delivery of genes encoding proteins whose role is to regulate calcium uptake or release in the sarcoplasmic reticulum.

IPSCIO Record ID: 29073

License Grant
The Licensee entered into an agreement with the University which granted us an exclusive worldwide license, with the right to sublicense, to certain technology covering development, manufacture, use and sale of gene therapy products based on FGF-4 for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure. FGF-4 shall mean Fibroblast Growth Factor 4, the amino acid sequence.
Field of Use
Field shall mean gene therapy for coronary artery disease, congestive heart failure, and peripheral vascular disease.

IPSCIO Record ID: 1340

License Grant
The Canadian Licensee holds an exclusive worldwide License to certain patent rights relating specifically to antisense and related technologies described in patent applications that were pending at the time of the Agreement with Licensor, a Canadian University.

Subsequent patent amendments or advancements to these patents remain as the property of the Licensee, without License rights accruing back to the Licensor.

License Property
Antisense refers to short DNA or RNA sequences, termed oligonucleotides, which are designed to be complementary to a specific gene sequence. The goal is to alter specific gene expression resulting from the binding of the antisense oligonucleotide to a unique gene sequence.

IPSCIO Record ID: 203318

License Grant
Licensor grants to the Japanese Licensee and its Affiliates, an exclusive license under Patent Rights, to make, have made, use, import, sell, offer to sell and have sold the Licensed Products within the Licensed Field in the Licensed Territory. No license is granted outside the Licensed Field.
License Property
HGF Gene shall mean DNA sequences corresponding to the mRNA sequence defined by Genbank Accession number NM_000601 encoding human HGF, known variously as hepatocyte growth factor, hepapoietin A, and scatter factor, which when expressed affords the human HGF protein or any isoform or therapeutically active truncation thereof.

IHD means ischemic heart disease.  PAD means peripheral arterial disease or any other use with the exception of IHD. Angiogenesis means stimulation of new blood vessel growth in the context of cardiovascular disease.

Field of Use
Licensed Field shall mean the manufacture, use and/or sale of the Licensed Products using the HGF Gene in gene therapy applications.

IPSCIO Record ID: 260407

License Grant
University grants to Licensee a license under Universitys interest in Patent Rights to make, use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods in the Field, within the Territory and during the Term.  The amendment adds the patent information.

The licenses granted in this paragraph is exclusive with respect to the Field only.

License Property
The patent is for the therapy treatment or prevention of cardiovascular disease.
Field of Use
The Field means gene therapy for the treatment or prevention of cardiovascular diseases by the delivery of a gene or a synthetic equivalent (DNA, deoxyribonucleic acid or polydeoxyribonucleotide sequence), in whole or in part or in combination, including those encoding one or more phospholamban genes and/or SERCA-2 (sacroplasmic reticulum calcium ATPase) genes, or their mutants, excepting the involvement of anti-sense RNA (ribonucleic acid or polyribonucleotide sequence) of the phospholamban gene.

IPSCIO Record ID: 27156

License Grant
The Company hereby grants to InterMune the exclusive sublicense under the Genentech License Rights to develop, use, sell, offer for sale, import, make and have made Licensed Protein Products in the IG Field in the Territory.
License Property
Gene Therapy means the therapeutic or prophylactic treatment of a human being with (a) one or more oligonucleotides or nucleotide sequences.
Field of Use
IG Field means the administration to humans of Licensed Protein Product for the treatment or prevention of any human disease or condition, provided however, that IG Field shall not include (i) the administration to humans of Licensed Protein Product for the treatment or prevention of any type of arthritis or cardiac or cardiovascular disease or condition or (ii) use of Licensed Protein Product for Gene Therapy.

Gene Therapy field means the administration to humans of Licensed Gene Product for Gene Therapy for the treatment or prevention of any human disease or condition, provided however, that Gene Therapy Field shall not include any treatment or prevention of any type of cardiac or cardiovascular disease or condition.  Immunology-based products.

IPSCIO Record ID: 1417

License Grant
The Licensor hereby grants to Licensee of the Netherlands in the License Field in the License Territory
(i) an exclusive, royalty-bearing license under its rights in Patent Rights to make, have made, use, have used, Sell and have Sold Products and Processes; and
(ii) the right to grant sublicenses under the rights granted (a)(i) to Sublicensees.
License Property
Technology relates to a patent family with claims directed to an alternative RNA repair platform that uses an RNA oligonucleotide complex rather than a single stranded oligonucleotide. This patent family includes an issued U.S. patent with a composition of matter claim directed to an RNA oligonucleotide complex containing two specific oligonucleotide sequences for modulating the expression or activity of a CFTR gene product, and an allowed U.S. patent application with method of use claims relating to the treatment of a symptom of cystic fibrosis in a subject by administering to the subject an RNA oligonucleotide complex comprising two oligonucleotides, as well as a composition of matter claim directed to a specific RNA complex for modulating the activity of a CFTR gene product.
Field of Use
License Field shall mean all therapeutic indications in the field of Cystic Fibrosis.

The Licensee was founded in May 2012 with the goal of developing a treatment for cystic fibrosis.

IPSCIO Record ID: 383599

License Grant
For the Product License, Licensor grants an exclusive license, with the limited right to sublicense, under the Licensed IP to research, develop, make, have made, use, sell, offer for sale, have sold, import and export Products in the Territory for therapeutic purposes.

For the Limited Right to Sublicense, the Product License is sublicensable only in connection with a sublicense of a Product to any Affiliate of Licensee or to any Third Party,

License Property
Licensor has intellectual property to advance mipomersen and related compounds targeting apoB.

Mipomersen means mipomersen sodium, including all pharmaceutically acceptable salts, solvates, hydrates, hemihydrates, metabolites, pro-drug forms, stereoisomers, enantiomers, racemates and all optically active forms thereof.

apoB means apolipoprotein B.

Product means all pharmaceutical compositions, formulations, dosage forms, delivery systems and presentations that contain Mipomersen or any Follow-On Compound as an active ingredient.

ASO Product any preparation in final form for sale by prescription, over-the-counter or any other method for any indication, including human or animal use, which contains one or more oligonucleotides or an analog thereof that  selectively modulates protein synthesis at the nucleic acid level through the binding of such oligonucleotide to a complementary sequence.

FH means familial hypercholesterolemia.

Licensed Product Patents means the Shortmer Patent, and any Patent Controlled by Isis during the Term, including any Licensor Program Patents and Joint Patents, claiming nucleic acids that hybridize to a nucleic acid molecule encoding apoB, the sequence of apoB. the specific composition of matter of a Product, or methods of using Product as a therapeutic, methods of using Product to modulate apoB, and methods of using the Product to inhibit expression of apoB- and also claiming or describing (x) nucleic acids that hybridize to a nucleic acid molecule encoding a gene target other than apoB or ( y) methods of using such nucleic acids as a therapeutic or to modulate a gene target other than apoB.

Field of Use
The field of use is to treat homozygous familial hypercholesterolemia.  Homozygous familial hypercholesterolemia is a disorder where it is hard for your body to remove LDL 'bad' cholesterol from your blood. The disease raises your chances of a heart attack at an early age, but drugs and other treatments can lower your risk.

Licensee will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high risk cardiovascular patients that utilizes novel antisense technology.  Mipomersen, formerly ISIS 301012, is a lipid-lowering drug targeting apolipoprotein B-100. Currently in phase 3 development, mipomersen has been shown in phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with current standard lipid-lowering drugs, enabling more patients to achieve lipid targets.

IPSCIO Record ID: 250968

License Grant
For the Exclusive License,  Licensor grants an exclusive, worldwide license, with the right to sublicense, to Licensor Intellectual Property that relates to a Joint p53-PMO Item, solely in the Licensee Field, to research, develop, make, have made, use, import, put into use, modify, distribute, offer for sale, sell and have sold Licensed Licensor IP Products and to practice Licensed Licensor IP Methods during the term of this Agreement.

For the Semi-Exclusive License, Licensor shall grant a semi-exclusive, worldwide license to Licensor Intellectual Property that relates to a Joint p53-PMO Item, solely in the Joint Field and within the context of such joint development activities with Licensor, to research, develop, make, have made, use, import, put into use, modify, distribute, offer for sale, sell and have sold Licensed Licensor IP Products and to practice Licensed Licensor IP Methods during the term of this Agreement.

License Property
The patents licensed include Antisense Oligonucleotides to p53, and, Methods and compositions for selectively treating cancer cells characterized by p53 expression, and, Therapeutic Oligonucleotides targeting human MDR-! and MRP Genes, and, Methods and compositions for treatment of cancer using Oligonucleotides, and, Methods and Compositions for Cellular Reprogramming.

p53 is a protein.  PMO refers to  phosphorodiamidate morpholino oligomer chemistry.

Antisense drugs targeting p53 is a well-studied human protein that controls cellular response to genetic damage.

Field of Use
Licensees main field of interest in p53-PMO technology is as a potential target for antiviral therapies, and the Parties wish to cooperate in the development and commercialization of therapies using p53-PMO technology in other fields.

IPSCIO Record ID: 26103

License Grant
The asset purchased with the company is a novel gene therapy through preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF).
License Property
Licensor is an early-stage biotechnology company,effectively a single-product business, fully focusing on the further development of gene therapy approaches for cardiac disease.

IPSCIO Record ID: 230823

License Grant
Licensor grants to an irrevocable, worldwide, sublicensable, exclusive license to the Technology to make, have made, use, import, export, distribute, sell, offer to sell and have sold the Drug in the Field and to make, have made, use, import, export, distribute, sell, offer to sell and have sold products incorporating or utilizing the Drug and/or the Technology in the Field, practice methods covered thereby, and otherwise to commercialize and exploit, the Drug and/or the Technology in the Field.
License Property
Licensor has developed technology relating to antisense compounds, including Resten NGâ„¢.

Resten-NG is a third-generation NeuGene® antisense compound, is designed to address the underlying genetic mechanism that leads to restenosis. The result is that this compound can selectively target multiple aspects of the restenosis response, specifically cellular proliferation, secretion of matrix proteins and inflammation, potentially without impeding vascular healing.  Restenosis is the renarrowing or reclogging of arteries following balloon angioplasty or placement of a stent.  Resten-NG is currently in Phase II clinical trials.

Compound means any drug as defined in the Federal Food, Drug and Cosmetic Act, as amended, not licensed hereunder and all derivatives and analogues of such drug, any biological product as defined in the Public Health Service Act, as amended, not licensed hereunder and all derivatives and analogues of such biological product and the antisense compounds not licensed hereunder.

The patents include morpholino-based polymers, sequence-specific polynucleotide-binding polymers, antisense oligonucleotides, and, method for blocking proliferation of a non-transformed cell in vivo or in vitro.

Field of Use
Field means the treatment of vascular disease only in conjunction with the use of a stent, balloon, catheter or any other medical device (other than a medical device providing for systemic application). The parties acknowledge that the Field docs not include the treatment of hypertension or congestive heart failure except as may occur through the treatment of restenosis or atherosclerosis.

IPSCIO Record ID: 352695

License Grant
University grants an exclusive, worldwide license in the Patent Rights to make, have made, use, offer for sale, sell, have sold and import Licensed Products in the Field.
License Property
The patents include
–  Allele-specific RNA Interference;
–  In Vivo Production of Small Interfering RN As that Mediate Gene Silencing;
–  RNA Interference for the Treatment of Gain-of-Function Disorders;
–  Novel AAVs and Uses Thereof;
–  CNS Targeting AAV Vectors and Methods of Use Thereof;
–  Methods and Compositions for Controlling Efficacy of RNA Silencing;
–  Methods and Compositions for Enhancing the Efficacy and Specificity of Single and Double Blunt-Ended siRNA; and,
–  Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi.
Field of Use
The Field of use is the treatment of human diseases using gene therapy applications.  Any commercial sale of research reagents covered by the Patent Rights is specifically excluded
from the Field.

The gene therapy approach uses AAV (adeno-associated virus) vectors, which are modified, non-replicating versions of AAV, and which we believe are ideal vectors for CNS gene therapy.

The Licensee expects to utilize established and novel techniques for dosing and delivery of our AAV gene therapies to the CNS.

IPSCIO Record ID: 203266

License Grant
Licensor grants, during the Term, an exclusive license, under the Technology to Licensee Products in the Field.
License Property
This technology includes, without limitation, MYDICAR® (AAV1/SERCA2a).

Mydicar is a genetically targeted enzyme replacement therapy being studied for use in patients with severe heart failure.  It is designed to increase the level of SERCA2a, a sarcoplasmic endoplasmic reticulum calcium (Ca2+) ATPase found in the membrane of the sarcoplasmic reticulum (SR). The SERCA2a gene is delivered to the heart via an adeno-associated viral vector.

Field of Use
The field is human therapeutics and prophylactics.

IPSCIO Record ID: 260409

License Grant
Licensor grants a non-exclusive, worldwide license, including the right to grant sublicenses through multiple tiers of sublicense, under the Patent Rights solely to develop, make, have made, use, offer for sale, sell, have sold, import, have imported, export and have exported Products in the Field of Use.
License Property
The patent relates to genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell.
Field of Use
The Field of Use shall mean the production and delivery of adeno-associate viral vector (AAV) Serotype 1 to deliver SERCA 2a for the treatment of heart failure and arrhythmias.

IPSCIO Record ID: 3533

License Grant
The Licensor and the Licensee entered into an Assignment and License Agreement, pursuant to which the Licensor granted the Licensee an exclusive, worldwide license and the assignment of patents relating to certain gene therapy applications of mSCF for the treatment of cardiac ischemia. The Licensee has the right to grant sublicenses to third parties under the agreement.
License Property
Licensor owns certain intellectual property (including an issued United States patent) relating to certain gene therapy methods for delivering stem cell factor coding sequences, in order to treat certain ischemic diseases.

The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.

The Licensor intellectual property and research involves gene therapy technologies.

Field of Use
The Licensee will use the rights to gene therapy applications for the membrane bound form of Stem Cell Factor, or mSCF, for treatment of cardiac ischemia.  Cardiac ischemia occurs when blood flow to your heart muscle is decreased by a partial or complete blockage of your heart's arteries. The decrease in blood flow reduces your heart's oxygen supply and can damage your heart muscle, reducing its ability to pump efficiently.

IPSCIO Record ID: 328338

License Grant
Licensor grants the Licensee of Japan the right and license, with no right to sublicense except as provided under the Licensor Patents and the Know-How, solely to use the Licensed Compounds to conduct Development and to import, use, and sell Products solely for use in the Field within the Territory.

For Other Indications for Licensed Compounds, Licensor grants a right of first refusal to obtain licenses to use Licensed Compounds for other applications or indications outside the Field.

For Rights to Related Compounds. Licensor grants the right to include within the license rights granted under the License specific Related Compounds.

The Parties are to develop  and  commercialize LR-3280 and certain related oligonucleotide compounds in Japan and certain other countries in Asia for the prevention or treatment of restenosis in any blood vessel  following an angioplasty or similar procedure,  and Licensor will supply Licensee quantities of product containing such compounds for clinical use and commercial sale.

License Property
Licensor is engaged in research and  development of, among other things, oligonucleotides and oligonucleotide  analogs that may be useful for therapeutic treatment of disease conditions.   Licensor is presently developing  one such oligonucleotide compound, identified as LR-3280 targeted to c-myc mRNA, as a pharmaceutical product for the prevention or treatment of restenosis in any blood vessel following an angioplasty or similar procedure.

The patents subject matter includes but is not limited to
–  Method of inhibition smooth muscle cell proliferation by treating with c-myc antisense;
–  Method of treating restenosis by administrating c-myr antisense;
–  Method of Inhibiting collagen synthesis by treating with c-myr antisense;
–  Method of treating vascular grafts to reduce stenosis by applying c-myr antisense to graft; and,
–  Pharmaceutical compositions for the above methods.

Licensed Compounds means the oligonucleotide compound identified by Licensor as LR-3280, and any other phosphorothioated oligonucleotidc compounds that now or hereafter are owned or Controlled by Licensor or its Affiliates and that specifically target the mRNA transcribed from the c-myc gene, or contain four deoxyguanosine nucleotides in a row and are developed by Licensor for use in the Field.

Clinical Trial Product means a product,  appropriate for use in clinical trials, containing a Licensed  Compound or placebo, as applicable, in the formulation as determined by Licensee.

Field of Use
Field means the prevention or treatment of restenosis in humans in any blood vessel by use of a Licensed Compound delivered to the affected blood vessel via a Delivery Means following any stenosis-reducing medical procedure that is Transient in nature and that is intended to reduce the obstruction of the blood flow in a stenosed vessel (including without limitation percutaneous transluminal angioplasty, percutaneous transluminal coronary angioplasty and angioplasty involving placement of an intravascular stent).

Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.

IPSCIO Record ID: 240578

License Grant
The University grants a worldwide, exclusive license under Licensed Subject matter to discover, research, develop, make, have made, use offer for sale, sell and import Licensed Products and Identified Products for use within Licensed Field.
License Property
Licensed Product means any compound, assay, method, reagent, technology, product or service comprising Licensed Subject Matter.

Licensed Subject Matter means inventions, discoveries, assays and processes covered by Patent Rights and/or Technology Rights within Licensed Field.

The patents are for Methods and Compositions Relating to Muscle Selective Calcineurin Interacting Protein (MCIP).

Field of Use
Licensed field means treatment, prevention, diagnosis and/or prognosis of cardiac hypertrophy, heart disease and heart failure; and determination of predisposition to cardiac hypertrophy, heart disease and heart failure.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.